Tompsett was, until recently, a senior partner at PriceWaterhouseCoopers, responsible for the firm’s global cross border IPO practice. For several years, he led the firm’s UK and European activities in the pharmaceutical sector, advising on large deals.

At Cello he will head the board's audit committee and be the company's senior independent director.

LeCouilliard was most recently at GlaxoSmithKline where she held senior executive positions globally in the US and Asia. She has also held senior hospital management positions at BMI Healthcare, and is currently a non-executive director of Circassia Pharmaceuticals. 

Paul Hamilton and Will David have both stood down as non-executive directors, having sat on the board for more than a decade.